Cite
HARVARD Citation
Milhem, M. et al. (n.d.). 304 Intratumoral injection of CMP-001, a toll-like receptor 9 (TLR9) agonist, in combination with pembrolizumab reversed programmed death receptor 1 (PD-1) blockade resistance in advanced melanoma. Journal for immunotherapy of cancer. p. A331. [Online].